君实生物 - Financials

Line Item	FY 2025Dec 31, 2025	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021
+Revenue	2.5B	1.9B	1.5B	1.5B	4.0B
Revenue Growth %	28.2%	29.6%	3.4%	-63.9%	--
Total Revenue	2.5B	1.9B	1.5B	1.5B	4.0B
Cost Of Revenue	467.0M	411.0M	541.0M	504.0M	1.2B
+Gross Profit	2.0B	1.5B	962.0M	949.0M	2.8B
Gross Margin %	81.3%	78.9%	64.0%	65.3%	69.1%
Total Operating Cost	3.5B	3.3B	4.0B	4.1B	4.7B
Selling Expenses	1.1B	985.0M	844.0M	716.0M	735.0M
Admin Expenses	494.0M	523.0M	536.0M	569.0M	642.0M
Rd Expenses	1.3B	1.3B	1.9B	2.4B	2.1B
Finance Expenses	65.3M	-144,400	-67.1M	-81.0M	31.4M
+Operating Income	-999.0M	-1.3B	-2.5B	-2.7B	-558.0M
Operating Margin %	-40.0%	-68.7%	-163.5%	-183.5%	-13.9%
Non Operating Income	777,300	2.3M	3.9M	683,000	79,600
Non Operating Expenses	24.6M	21.0M	38.2M	12.0M	36.8M
Investment Income	-106.0M	-23.6M	74.0M	-41.9M	-47.2M
Fair Value Change Income	57.2M	-47.7M	-149.0M	-9.3M	113.0M
Asset Disposal Income	35.3M	12.8M	29.4M	22.6M	812,900
Asset Impairment Loss	98.1M	88.2M	126.0M	22.0M	13.6M
Other Income	55.2M	55.6M	47.4M	34.2M	91.9M
Income Before Tax	-1.0B	-1.4B	-2.5B	-2.7B	-595.0M
Income Tax	-13.9M	22.6M	44.0M	-93.1M	136.0M
+Net Income	-1.0B	-1.4B	-2.5B	-2.6B	-731.0M
Net Margin %	-40.4%	-70.8%	-168.7%	-177.8%	-18.2%
Net Income Attributable	-875.0M	-1.3B	-2.3B	-2.4B	-721.0M
Minority Interest	-134.0M	-99.2M	-252.0M	-196.0M	-9.6M
Eps Basic	-0.87	-1.30	-2.32	-2.60	-0.81
Eps Diluted	-0.87	-1.30	-2.32	-2.60	-0.81

Line Item	FY 2025Dec 31, 2025	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021
Cash And Equivalents	2.6B	2.5B	3.8B	6.0B	3.5B
Trading Financial Assets	601.0M	431.0M	--	--	--
Accounts Receivable	506.0M	510.0M	483.0M	238.0M	1.3B
Notes Receivable	302,000	--	--	--	7.7M
Notes And Accounts Receivable	507.0M	510.0M	483.0M	238.0M	1.3B
Prepayments	144.0M	200.0M	239.0M	231.0M	390.0M
Inventory	573.0M	584.0M	538.0M	599.0M	485.0M
Total Current Assets	4.5B	4.3B	5.6B	7.2B	5.8B
Long Term Equity Investment	508.0M	223.0M	243.0M	493.0M	458.0M
Fixed Assets	2.2B	2.3B	2.4B	1.9B	1.9B
Fixed Assets Total	2.2B	2.3B	2.4B	1.9B	1.9B
Construction In Progress	2.6B	1.9B	1.3B	1.0B	802.0M
Construction In Progress Total	2.6B	1.9B	1.3B	1.0B	802.0M
Intangible Assets	560.0M	521.0M	547.0M	316.0M	265.0M
Long Term Deferred Expenses	9.8M	6.1M	12.6M	23.2M	27.8M
Total Non Current Assets	7.9B	6.5B	5.8B	5.3B	5.2B
Total Assets	12.4B	10.8B	11.3B	12.6B	11.0B
Short Term Borrowings	603.0M	678.0M	452.0M	351.0M	--
Accounts Payable	1.1B	1.2B	1.4B	1.1B	1.6B
Advance Receipts	--	--	--	--	--
Contract Liabilities	22.2M	8.2M	146.0M	4.1M	45.8M
Total Current Liabilities	2.8B	2.5B	2.4B	1.8B	2.0B
Long Term Borrowings	2.8B	2.0B	1.2B	840.0M	490.0M
Total Non Current Liabilities	3.5B	2.4B	1.6B	1.0B	717.0M
Total Liabilities	6.3B	4.8B	4.0B	2.8B	2.7B
Paid In Capital	1.0B	986.0M	986.0M	983.0M	911.0M
Capital Reserve	16.4B	15.4B	15.4B	15.3B	11.4B
Retained Earnings	-11.2B	-10.3B	-9.1B	-6.8B	-4.4B
Minority Equity	26.2M	71.7M	169.0M	293.0M	371.0M
Equity Attributable	6.0B	5.9B	7.2B	9.5B	7.9B
Total Equity	6.1B	5.9B	7.3B	9.8B	8.3B

Line Item	FY 2025Dec 31, 2025	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021
Cash From Sales	2.7B	1.8B	1.5B	2.4B	3.3B
Tax Refunds Received	35.3M	10.5M	144.0M	300.0M	72.4M
Total Operating Cash Inflow	2.8B	1.9B	1.7B	2.7B	3.5B
Cash Paid For Goods	1.8B	1.7B	2.1B	3.0B	2.7B
Cash Paid To Employees	1.2B	1.2B	1.3B	1.3B	1.1B
Taxes Paid	112.0M	89.1M	78.5M	38.4M	29.2M
Total Operating Cash Outflow	3.4B	3.4B	3.7B	4.5B	4.1B
Operating Cash Flow	-520.0M	-1.4B	-2.0B	-1.8B	-605.0M
Total Investing Cash Inflow	2.3B	2.0B	1.4B	152.0M	596.0M
Total Investing Cash Outflow	3.9B	2.9B	2.3B	589.0M	2.5B
Investing Cash Flow	-1.6B	-893.0M	-933.0M	-437.0M	-1.9B
Cash From Borrowings	3.6B	2.3B	977.0M	840.0M	500.0M
Dividends And Interest Paid	94.3M	73.8M	38.2M	19.2M	16.7M
Debt Repayments	2.4B	1.2B	481.0M	113.0M	793.0M
Total Financing Cash Inflow	4.8B	2.3B	1.3B	5.0B	3.5B
Total Financing Cash Outflow	2.5B	1.3B	629.0M	411.0M	851.0M
Financing Cash Flow	2.2B	1.0B	712.0M	4.6B	2.7B
Net Change In Cash	107.0M	-1.3B	-2.2B	2.5B	120.0M
Ending Cash Balance	2.6B	2.5B	3.8B	6.0B	3.5B
Capex	768.0M	691.0M	833.0M	394.0M	902.0M